BioSpace News Archive

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from several studies at the 2019 Annual Clinical and Scientific meeting of The American College of Obstetricians and Gynecologists (ACOG) being held May 3-6, 2019 in Nashville, Tenn.

SkinBioTherapeutics has appointed Stuart Ashman as an executive director, effective from April 18th.. Stuart will succeed Professor Cath O’Neill as CEO after a period of transition, which will enable him to gain an understanding of the science based company which is focused on skin health

Transcatheter Aortic Valve Replacement Technology for Patients with Severe Aortic Stenosis Designed to Minimize Paravalvular Leakage, Offer Controlled Delivery and Repositionability Post Deployment

Through a revolving credit facility, SFS purchases the debt from Siemens on behalf of the customer and then gives the customer flexible repayment options with a choice of when to pay, up to 180 days.

BioStrata is proud to confirm that Her Majesty The Queen has approved the Prime Minister’s recommendation that the company should receive a Queen’s Award for Enterprise: International Trade.

Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that two abstracts reporting updated clinical data from ongoing Phase I/IIa trials with SRA737 have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held between 31 May – 4 June 2019 (Chicago, IL, USA).

Patients with Absence Epilepsy show generalized, non-convulsive seizures & typical Spike-and-Wave Discharges.

Rogers, a seasoned pharmacy professional, brings decades of pharmacy expertise to TDS in the newly created role

Jhpiego, an international health nonprofit affiliate of Johns Hopkins University, will honor Wyck Godfrey, President of Paramount’s Motion Picture Group, and Dr. Mary Kerr, prominent Los Angeles obstetrician-gynecologist, at its April 29 gala in appreciation for the couple’s outstanding philanthropic efforts to support women and families.

Approval based on clinical trials showing people treated with SKYRIZI™ (risankizumab-rzaa) every 12 weeks - four doses a year after two initial doses - achieved high levels of durable skin clearance at 16 weeks and maintained this response at one year[1-3]